``

Concord Biotech: Analyzed by Antique Stock Broking

Key Points

• Antique Stock Broking recommends buying Concord Biotech.
• Company’s growth is driven by becoming fully integrated.
• Strong business model: long contracts, high barriers to entry.
• Expected revenue and profit growth of 18-19% over 5 years.
• Stock valued at ₹1,520, representing a 16% potential gain.
• Shares are up 1.8% today, trading near ₹1,331.10.

What’s the Bottom Line?

Businesses can change quickly, and sometimes, a company’s plans don’t go exactly as expected. But, Antique Stock Broking believes Concord Biotech has good ideas and is likely to do well in the future.

Antique Stock Broking is saying Concord Biotech is a good investment. They think the company will get bigger and more successful because it’s changing how it does things. They’re building its business so it can make more products itself, instead of buying them from other companies.

Here’s how they think it will happen: The company has long-term deals with customers, making it difficult for others to compete. They also make medicines in a special way that costs more, keeping other companies out. Plus, they are starting to make their own ingredients for the medicines, and they are creating a new factory to make injectable medicines. This will make the company more profitable.

The experts say that Concord Biotech is expected to grow its sales and profits by about 18% to 19% over the next five years. They also believe the company can keep its profits steady around 42%.

They think the stock is currently priced fairly. They value the stock at about ₹1,520, which means it could go up by almost 16% from where it is now. They based this on how much money the company is expected to make in the future.

On Tuesday, October 24, 2023, Concord Biotech’s stock was trading at ₹1,331.10. This means it went up a little bit compared to the day before. The stock also reached a high point of ₹1,352.20 during the trading day.

Concord Biotech makes a lot of money – around ₹13,925.46 crore. This is the total value of all the company’s shares.

The experts also pointed out some key things about Concord Biotech’s business. First, they make special ingredients for medicines (called “APIs”) and use a lot of them to make their own medicines. They expect this to grow by about 10% each year.

Second, the company is starting to make injectable medicines for other companies. They’ve been approved to make these medicines, and they plan to make more of them over the next few years. This is called “CDMO,” which stands for contract development and manufacturing organization.

Finally, the experts said that Concord Biotech’s ingredients are special and hard to find, which means they can charge more for them. There aren’t many other companies that make these ingredients, so Concord Biotech has an advantage.

“A company’s future success depends on how well it adapts to changes and executes its plans.”

`